tiziana
life
sciences
plc
publication
research
note
london
new
york
globe
newswire
tiziana
life
sciences
plc
nasdaq
tlsa
aim
tils
tiziana
company
pleased
note
publication
new
analyst
research
note
h
c
wainwright
co
available
company
website
https
tiziana
life
sciences
tiziana
life
sciences
plc
dual
listed
nasdaq
tlsa
uk
aims
tils
biotechnology
company
focuses
discovery
development
novel
molecules
treat
human
diseases
oncology
inflammation
infectious
diseases
addition
milciclib
company
shortly
initiating
phase
studies
orally
administered
foralumab
crohn
disease
nasally
administered
foralumab
progressive
multiple
sclerosis
foralumab
fully
human
monoclonal
antibody
mab
clinical
development
world
phase
ii
compound
potential
application
wide
range
autoimmune
inflammatory
diseases
crohn
disease
multiple
sclerosis
diabetes
inflammatory
bowel
disease
ibd
psoriasis
rheumatoid
arthritis
modulation
response
desirable
company
accelerating
development
receptor
mab
fully
human
monoclonal
antibody
treatment
inflammation
especially
treatment
patients
enquiries
united
kingdom
tiziana
life
sciences
plc
gabriele
cerrone
chairman
founder
cairn
financial
advisers
llp
nominated
adviser
liam
murray
jo
turner
optiva
securities
limited
broker
robert
emmet
united
states
investors
dave
gentry
redchip
companies
dave
